AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 11 - (NewsRx.com & NewsRx.net) -- Recombinant MVA ROP2 vaccinia virus is a vaccine candidate for toxoplasmosis.
According to a study from Mexico, "Toxoplasma gondii is the etiological agent of toxoplasmosis and is the most frequent and best known of the parasitic diseases. In the United States, a serological Survey from the Third National Health and Nutrition Examination Survey found that an estimated 23% of adolescents and adults have laboratory evidence of infection with T. gondii. Although toxoplasmosis is asymptomatic or shows self-limited symptoms in adults, in pregnant women infections can cause severe health problems to the fetus if the parasites are transmitted."
"Also, in immunodeficient patients, chronic infection with T. gondii can reactivate and produce encephalitis, which is frequently lethal," said J. L. Roque-Resendiz and colleagues at the National Autonomous University of Mexico. "In addition, in veterinary medicine, T. gondii infection is of economic importance due to abortion and neonatal loss in sheep and goats. Recently, the development of vaccines against toxoplasmosis has progressed considerably. The live attenuated S48 strain of Toxoplasma has been broadly used for veterinary purposes. DNA vaccines containing the full-length of SAG1/P30, ROP2 or ROP1 genes have proved to be a promising candidate to induce protection against toxoplasmosis."
"Viral vectors have proved to be the best candidates for vaccination in different diseases," stated the researchers. "A recombinant herpes virus carrying the ROP2 gene is able to induce ...
Source: HighBeam Research, MVA ROP2 vaccinia virus is vaccine candidate for toxoplasmosis.